In the phase III NAPOLI-3 trial, first-line treatment with NALIRIFOX was associated with improved overall survival compared to gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Here the authors report the results of a randomized phase II trial comparing the two regimens, NALIRIFOX versus Gemcitabine plus Nab-Paclitaxel, in Chinese patients.
- Chuntao Gao
- Yanqiao Zhang
- Jihui Hao
